What exactly did Cantor Fitzgerald change for Everus on February 26, 2026?

Cantor Fitzgerald maintained a Neutral rating on Everus (ECG) and raised its price target to $115 on February 26, 2026. The firm cited constructive market conditions but did not upgrade to Buy or downgrade to Sell.

How should investors interpret the ECG analyst rating now?

The ECG analyst rating being Neutral with a higher PT means analysts see valuation upside but not enough conviction for a Buy. Investors should watch quarterly results and backlog updates before shifting exposure materially.

Does the new price target mean the stock will rise to $115?

A price target is an analyst’s outlook, not a guarantee. The raised PT to $115 reflects Cantor Fitzgerald’s view under constructive conditions; actual stock movement depends on earnings, execution, and market sentiment.

How significant is analyst coverage for ECG going forward?

Coverage for ECG is relatively limited, so each published ECG analyst rating or PT change can have an outsized impact. Investors should follow multiple data points and news flow rather than relying on a single analyst update.

Analyst Ratings

Cantor Fitzgerald Maintains Neutral on Everus (ECG) Feb 2026, PT $115

ByHuzaifa Zahoor February 27, 2026

Cantor Fitzgerald on February 26, 2026 maintained a Neutral rating on Everus Construction Group, Inc. (ECG) while raising its price target to $115. This update is the primary change in recent analyst activity and directly affects how investors interpret the ECG analyst rating. Cantor framed the move around “constructive market conditions,” a cautious tone that keeps the rating steady but nudges valuation expectations. The call follows recent Q4 2025 results and a share price move that has been volatile, leaving investors to weigh a higher target against recent weakness.